38.5 million yen subsidy from NPO corporation supporting patients and families to the National Center for Global Health and Medicine for “Bioartificial Pancreatic Islet Clinical Practical Application”

Authorized Specified Nonprofit Corporation Japan IDDM Network 38.5 million yen subsidy from NPO corporation supporting patients and families to the National Center for Global Health and Medicine for “Bioartificial Pancreatic Islet Clinical Practical Application” November 25th (Friday) Presentation ceremony and press conference
Japan IDDM Network (Chairman: Tatsuo Inoue, Headquarters: Saga City), a certified NPO corporation that supports type 1 diabetes patients and their families nationwide, is the closest to a “permanent cure” for type 1 diabetes, which cannot be cured with current medical care. To date, we have provided a total of 214 million yen in research grants to the bio-artificial pancreatic islet transplantation project (transplantation of pig islets into humans) (as of November 11). This project is a domestic joint project that transcends the boundaries of faculties (specialties) by the National Center for Global Health and Medicine, Fukuoka University, Meiji University, Setsunan University, and Nihon University.
In order to further accelerate this project, we have extended research grants of 1 million yen in 2013, 30 million yen in 2015, 70 million yen in 2016, and 10 million yen in 2020 to the National Center for Global Health and Medicine. , We have decided to provide an additional 38.5 million yen in subsidies, so we will hold a presentation ceremony and press conference as follows.
We have provided a total of 149.5 million yen (including this grant) to the National Center for Global Health and Medicine. Thing. [Image

The “Shinichi Kaneiwa Fund” was established in 2022 with donations entrusted by the bereaved family of the late Shinichi Kaneiwa. Based on the will of Shinichi Kaneiwa, who wanted to contribute to research that could contribute to the realization of a complete cure for type 1 diabetes, and the wishes of his bereaved family, he will lead this research field in Japan toward the eradication of type 1 diabetes in the future. We would like to express our hope to researchers.
[Table 2: https://prtimes.jp/data/corp/38819/table/65_1_0de2fe0f3926a1bd2bb1d93d042e89e3.jpg ]
[About research grants]
〇 Research subject: Preclinical study for clinical practical use of bio-artificial pancreatic islets using porcine pancreatic islets 〇Researcher: Masayuki Shimoda, Director of Pancreatic Islet
Transplantation Corporate Collaboration Project, National Center for Global Health and Medicine
〇 Research funds: 38.5 million yen
〇 Research overview:
“Pancreatic islet transplantation” is expected to be a cure for type 1 diabetes, but there are problems with “lack of donors” and
“requirement of immunosuppressants”. To overcome this problem, we are developing a “bio-artificial pancreatic islet” in which porcine pancreatic islets, which are available in large quantities and at low cost, are encapsulated in special capsules.
However, new treatments like this need to be tested on a small number of patients to prove their efficacy and safety before they can be widely used. Prior to conducting this clinical trial, it is necessary to confirm the efficacy and safety by as many methods as possible other than transplanting to humans, such as animal experiments. The purpose of this research is to obtain sufficient data such as animal experiments called preclinical tests before clinical trials. We manufacture bio-artificial pancreatic islets and examine whether they have the required functions and whether they are effective when transplanted into animals. In addition, we will conduct improvement research that will lead to mass production and functional improvement with the aim of practical application of bioartificial pancreatic islets.
◆ Coverage/reporting method
Please join us using the online conference system app “Zoom” … Please prepare an environment and device that can connect to the Internet and participate online.
Pre-registration is required, so please apply by [Thursday, November 24] from the [Media Information] below.
≪What is type 1 diabetes?≫
It is an intractable disease with an unknown cause that often develops suddenly in childhood, and with current medical standards, it leads to death within a few days unless insulin is replenished by injections or pumps 4 to 5 times a day for the rest of one’s life. Type 2 diabetes is generally recognized as diabetes and accounts for the majority of diabetes patients. The emotional and financial burden on the family is heavy.
[About Japan IDDM Network]
The Japan IDDM Network aims to realize a society where patients who need insulin replacement and their families can live with hope. The immediate goal is to transform type 1 diabetes from an incurable disease to a curable disease, but the ultimate goal is to eradicate type 1 diabetes (= treatment + eradication + prevention).
Since the establishment of the Type 1 Diabetes Research Fund in 2005, the Japan IDDM Network has supported 122 research projects totaling 641.5 million yen (including this research grant).
Details about this release:
https://prtimes.jp/main/html/rd/p/000000065.000038819.html


rehow

One thought on “38.5 million yen subsidy from NPO corporation supporting patients and families to the National Center for Global Health and Medicine for “Bioartificial Pancreatic Islet Clinical Practical Application”

  1. It’s wonderful that you are getting ideas from
    this piece of writing as well as from our argument made here.

Leave a Reply

Your email address will not be published.

%d bloggers like this: